Drug intelligence / Profile preview

GS-221

Development stage: Unknown
Lead developer: Grand Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

GS-221 is an oral small molecule drug developed by Grand Pharmaceutical Group. It acts as a SARS-CoV-2 3CLpro inhibitor, targeting the 3-chymotrypsin-like protease of SARS-CoV-2. GS-221 is primarily indicated for the treatment of COVID-19. It has shown favorable safety and tolerance in clinical trials, with improvements in clinical symptoms and viral load reduction.

Targets

Mpro (3C-like proteinase of SARS-CoV-2)

Beyond the preview

Go deeper on GS-221.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GS-221.

Explore the full profile